NCT02542852 - A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

December 31, 2017

Conditions

HIV-1 Infection

Interventions

DRUG

atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg

Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks

Trial Locations (1)

Ospedale San Raffaele Scientific Institute, Milan